gip glp 1 glucagon agonists GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Effects, working principles and target

Methods A retrospective study was conducted using electronic medical records from 2014 to 2019 for adults with T2D at the Valencia Clnico-Malvarrosa Department of Health (Valencia, Spain)

The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity

In this Review, the possibilities for utilizing GLP-1 receptor agonists in individualized treatment for type 2 diabetes mellitus are discussed

How much GLP-1 do you take

Results Twenty-eight RCTs were ultimately included for analysis, involving a total of 77,485 participants

Background Alcohol use disorder (AUD) affects nearly half a billion people globally and is associated with significant physical and psychiatric comorbidities